To determine the role of CD154-CD40 interactions in the B cell overactivity exhibited by patients with active systemic lupus erythematosus (SLE), CD19+ peripheral B cells were examined before and after treatment with humanized anti-CD154 mAb (BG9588, 5c8). Before treatment, SLE patients manifested activated B cells that expressed CD154, CD69, CD38, CD5, and CD27. Cells expressing CD38, CD5, or CD27 disappeared from the periphery during treatment with anti-CD154 mAb, and cells expressing CD69 and CD154 disappeared from the periphery during the post-treatment period. Before treatment, active-SLE patients had circulating CD38 (bright) Ig-secreting cells that were not found in normal individuals. Disappearance of this plasma cell subset during treatment was associated with decreases in anti-double-stranded DNA (anti-dsDNA) Ab levels, proteinuria, and SLE disease activity index. Consistent with this finding, peripheral B cells cultured in vitro spontaneously proliferated and secreted Ig in a manner that was inhibited by anti-CD154 mAb. Finally, the CD38(+/++)IgD(+), CD38(+++), and CD38(+)IgD(-) B cell subsets present in the peripheral blood also disappeared following treatment with humanized anti-CD154. Together, these results indicate that patients with active lupus nephritis exhibit abnormalities in the peripheral B cell compartment that are consistent with intensive germinal center activity, are driven via CD154-CD40 interactions, and may reflect or contribute to the propensity of these patients to produce autoantibodies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC259134PMC
http://dx.doi.org/10.1172/JCI19301DOI Listing

Publication Analysis

Top Keywords

cd154-cd40 interactions
12
anti-cd154 mab
12
germinal center
8
systemic lupus
8
lupus erythematosus
8
patients active
8
peripheral cells
8
treatment humanized
8
humanized anti-cd154
8
cd38 cd5
8

Similar Publications

Differential induction of donor-reactive Foxp3 regulatory T cell via blockade of CD154 vs CD40.

Am J Transplant

August 2024

Emory Transplant Center and Department of Surgery, Emory University, Atlanta, Georgia, USA. Electronic address:

Recently published studies in both murine models and a meta-analysis of non-human primate renal transplant studies showed that anti-CD154 reagents conferred a significant survival advantage over CD40 blockers in both animal models and across multiple organs. Here we sought to compare the induction of donor-reactive forkhead box P3+-induced regulatory T cells (Foxp3 iTreg) in mice treated with anti-CD154 versus anti-CD40 monoclonal antibodies (mAbs). Results indicated that while treatment with anti-CD154 mAb resulted in a significant increase in the frequency of donor-reactive CD4 Foxp3 iTreg following transplantation, treatment with anti-CD40 or Cd40 deficiency failed to recapitulate this result.

View Article and Find Full Text PDF

CD40-CD154: A perspective from type 2 immunity.

Semin Immunol

March 2021

Área Inmunología, Departamento de Biociencias (Facultad de Química) and Cátedra de Inmunología, Instituto de Química Biológica (Facultad de Ciencias), Universidad de la República, Montevideo, Uruguay.

The interaction between CD40 and CD154 (CD40 ligand) is central in immunology, participating in CD4 T cell priming by dendritic cells (DC), CD4 T cell help to B cells and classical macrophage activation by CD4 T cells. However, its role in the Th2 side of immunology including helminth infection remains incompletely understood. Contrary to viral and bacterial stimuli, helminth products usually do not cause CD40 up-regulation in DC, and exogenous CD40 ligation drives Th2-biased systems towards Th1.

View Article and Find Full Text PDF

Many acute viral infections target tissue Mϕs, yet the mechanisms of Mϕ-mediated control of viruses are poorly understood. Here, we report that CD40 expressed by peritoneal Mϕs restricts early infection of a broad range of RNA viruses. Loss of CD40 expression enhanced virus replication as early as 12-24 h of infection and, conversely, stimulation of CD40 signaling with an agonistic Ab blocked infection.

View Article and Find Full Text PDF

CD11b is a novel alternate receptor for CD154 during alloimmunity.

Am J Transplant

August 2020

Emory Transplant Center and Department of Surgery, Emory University, Atlanta, Georgia.

Antagonism of the CD154/CD40 pathway is a highly effective means of inducing long-term graft survival in preclinical models. Using a fully allogeneic murine transplant model, we found that CD154 blockade was more effective in prolonging graft survival than was CD40 blockade, raising the possibility that CD154 binds a second receptor. To test this, we queried the impact of CD154 antagonism in the absence of CD40.

View Article and Find Full Text PDF

CD154 is a transmembrane cytokine expressed transiently on activated CD4 T cells upon T-cell receptor (TCR) stimulation that interacts with CD40 on antigen-presenting cells. The signaling via CD154:CD40 is essential for B-cell maturation and germinal center formation and also for the final differentiation of CD4 T cells during T-dependent humoral immune responses. Recent data demonstrate that CD154 is critically involved in the selection of T-cell clones during the negative selection process in the thymus.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!